Premium
NextCure Inc (NXTC)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. It is focused on understanding biological pathways, the interactions of cells and the role each in... NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. It is focused on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. The company's product candidate, NC318, is an immunomedicine against an immunomodulatory receptor called Siglec-15, or S15. Show more
BELTSVILLE, Md., Dec. 10, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and...
BELTSVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...
BELTSVILLE, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...
Prioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-endCash of approximately $75 million expected to fund operations into second half of 2026 BELTSVILLE...
Preclinical data for LNCB74 highlights its potential as therapeutic for treating multiple solid tumor indications; Investigational New Drug (IND) application filing expected by year-endAdditional...
BELTSVILLE, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.31 | -25.6198347107 | 1.21 | 1.21 | 0.9 | 98836 | 1.0732257 | CS |
| 4 | -0.5 | -35.7142857143 | 1.4 | 1.4 | 0.9 | 201179 | 1.14266713 | CS |
| 12 | -0.49 | -35.2517985612 | 1.39 | 1.6 | 0.9 | 90886 | 1.20819644 | CS |
| 26 | -0.7 | -43.75 | 1.6 | 1.8199 | 0.9 | 69323 | 1.33746897 | CS |
| 52 | -0.24 | -21.0526315789 | 1.14 | 2.57 | 0.9 | 130015 | 1.57537339 | CS |
| 156 | -4.81 | -84.238178634 | 5.71 | 6.48 | 0.9 | 119971 | 2.55110596 | CS |
| 260 | -50.93 | -98.2635539263 | 51.83 | 70.98 | 0.9 | 216015 | 11.45809241 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
